RecruitingPHASE1, PHASE2NCT06481306
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- BMS-986470(drug)
- Enrollment
- 184 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (19)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of California San Diego - La Jolla, La Jolla, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Yale-New Haven Hospital, New Haven, Connecticut, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Local Institution - 0034, Chicago, Illinois, United States
- Local Institution - 0001, Lenexa, Kansas, United States
- Local Institution - 0024, Boston, Massachusetts, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia, Pennsylvania, United States
- Local Institution - 0032, Pittsburgh, Pennsylvania, United States
- Inova Schar Cancer Institute, Fairfax, Virginia, United States
- Virginia Commonwealth University (VCU) Medical Center, Richmond, Virginia, United States
- Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, Alsace, France
- Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille, France
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06481306 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGPHASE1, PHASE2NCT06144749A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Hillhurst Biopharmaceuticals, Inc.
- RECRUITINGNANCT07064941Effect of Exercise on Body Composition and Bone Health in Patients With ThalassemiaUniversity of California, San Francisco
- ACTIVE NOT RECRUITINGNANCT06800495Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia ScreeningUniversiti Teknologi Mara
- ENROLLING BY INVITATIONNCT07003256Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCTHaikou Affiliated Hospital of Central South University Xiangya School of Medicine
- RECRUITINGNANCT06031714Fetal Cell Receptors RepertoireAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT06071377Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)National Alliance for Sickle Cell Centers